A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which
shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown
that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor
xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast
and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents,
indicating that APG-1252 may have a broad therapeutic potential for the treatment of human
cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252
is intended for the treatment of patients with neuroendocrine tumors. The purpose of the
phase 1b study to establish the maximum tolerated dose (MTD), and/or recommended phase 2 dose
(RP2D). Preliminary efficacy and pharmacokinetic properties will be aslo evaluated.